Goldman Sachs units trade and convert Attovia shares
Goldman Sachs–affiliated entities reported multiple transactions in Attovia Therapeutics common stock and preferred stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Goldman Sachs–affiliated entities reported multiple transactions in Attovia Therapeutics common stock and preferred stock. On completion of Attovia’s IPO, all redeemable convertible preferred stock automatically converted into common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split, and prior Form 3 conversion figures were corrected. GS&Co, acting as a market maker, bought 85,000 shares and sold 105,807 shares of common stock on August 5, 2026, and additional common shares were purchased in the IPO by affiliated investment vehicles.
Insights
Analyzing...
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
29 txns
Insider
GOLDMAN SACHS GROUP INC, GOLDMAN SACHS & CO. LLC, GOLDMAN SACHS ASSET MANAGEMENT, L.P., Broad Street Principal Investments, L.L.C., WSLS OFFSHORE INVESTMENTS, SLP, West Street Life Sciences I, L.P., WSLS EMP OFFSHORE INVESTMENTS, L.P., WSLS EMP ONSHORE INVESTMENTS, L.P.
Role
Insider | Insider | Insider | Insider | Insider | Insider | Insider | Insider
Bought
585,000 shs ($10.29M)
Sold
105,807 shs ($2.25M)
Approx. gross sale proceeds
$2.25M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Preferred Stock F4, F5, F1, F6, F7 | 18,181,830 | $0.00 | $0.00 |
| Conversion | Series C Preferred Stock F4, F5, F1, F6, F7 | 4,445,275 | $0.00 | $0.00 |
| Conversion | Common Stock F4, F5, F1, F6, F7 | 1,957,134 | $0.00 | $0.00 |
| Conversion | Common Stock F4, F5, F1, F6, F7 | 478,498 | $0.00 | $0.00 |
| Purchase | Common Stock F4, F1, F2 | 500,000 | $17.00 | $8.50M |
| Purchase | Common Stock F1, F2 | 85,000 | $21.00 | $1.78M |
| Sale | Common Stock F1, F2, F3 | 988 | $22.03 | $22K |
| Sale | Common Stock F1, F2, F3 | 447 | $21.87 | $10K |
| Sale | Common Stock F1, F2, F3 | 1,332 | $22.03 | $29K |
| Sale | Common Stock F1, F2, F3 | 200 | $22.05 | $4K |
| Sale | Common Stock F1, F2, F3 | 1,556 | $22.06 | $34K |
| Sale | Common Stock F1, F2, F3 | 3,402 | $22.02 | $75K |
| Sale | Common Stock F1, F2, F3 | 200 | $22.10 | $4K |
| Sale | Common Stock F1, F2, F3 | 480 | $21.55 | $10K |
| Sale | Common Stock F1, F2, F3 | 100 | $22.11 | $2K |
| Sale | Common Stock F1, F2, F3 | 753 | $21.97 | $17K |
| Sale | Common Stock F1, F2, F3 | 672 | $22.02 | $15K |
| Sale | Common Stock F1, F2, F3 | 6,970 | $22.03 | $154K |
| Sale | Common Stock F1, F2, F3 | 400 | $22.02 | $9K |
| Sale | Common Stock F1, F2, F3 | 1,180 | $21.84 | $26K |
| Sale | Common Stock F1, F2, F3 | 1,040 | $22.05 | $23K |
| Sale | Common Stock F1, F2, F3 | 300 | $20.84 | $6K |
| Sale | Common Stock F1, F2, F3 | 443 | $21.78 | $10K |
| Sale | Common Stock F1, F2, F3 | 200 | $22.05 | $4K |
| Sale | Common Stock F1, F2, F3 | 700 | $22.07 | $15K |
| Sale | Common Stock F1, F2, F3 | 1,163 | $22.19 | $26K |
| Sale | Common Stock F1, F2, F3 | 100 | $21.99 | $2K |
| Sale | Common Stock F1, F2, F3 | 6,763 | $21.61 | $146K |
| Sale | Common Stock F1, F2, F3 | 76,418 | $21.04 | $1.61M |
Holdings After Transaction:
Series B Preferred Stock — 0 contracts (Indirect, See footnotes);
Series C Preferred Stock — 0 contracts (Indirect, See footnotes);
Common Stock — 3,020,632 shares (Indirect, See Footnotes)
Footnotes (7)
- F1. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
- F2. These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
- F3. GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares.
- F4. The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4.
- F5. All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO").
- F6. This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7)
- F7. (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group.
Key Figures
Preferred shares converted (derivative exercises): 22,627,105 shares
Underlying common from conversions: 2,435,732 shares
Common shares bought (trades): 585,000 shares
+5 more
8 metrics
Preferred shares converted (derivative exercises)
22,627,105 shares
Total derivative exercise shares across Series B and Series C preferred stock
Underlying common from conversions
2,435,732 shares
Common stock underlying the reported preferred stock conversions
Common shares bought (trades)
585,000 shares
Total common shares reported as purchases across transactions
Common shares sold (trades)
105,807 shares
Total common shares reported as sales across transactions
Net share change from trades
479,193 shares
Net-buy direction across reported common stock purchases and sales
IPO purchase price example
$17.00 per share
Indirect purchase of 500,000 common shares at $17.00
Market-making sale price range
$20.84–$22.19 per share
Reported prices for August 5, 2026 common stock sales
Reverse stock split ratio
1-for-9.29
Reverse split effective July 29, 2026, applied before IPO conversion
Key Terms
market maker, redeemable convertible preferred stock, reverse stock split, initial public offering, +1 more
5 terms
market maker market
"transactions in the common stock of the Issuer were effected by GS&Co acting as a market maker"
A market maker is a firm or individual that stands ready to buy and sell a particular stock or other security throughout the trading day, posting prices at which it will transact so buyers and sellers can trade quickly. Think of it as a shopkeeper who keeps inventory and posts prices to ensure someone can always buy or sell; this reduces delays, narrows price swings, and helps investors execute trades at fairer, more predictable prices.
redeemable convertible preferred stock financial
"All shares of the Issuer's redeemable convertible preferred stock automatically converted"
A redeemable convertible preferred stock is a special class of company shares that combines three features: it pays priority dividends like a safer, higher-ranking share; it can be converted into regular common shares so holders can join in upside; and it can be redeemed, meaning the company can buy it back for cash. For investors this matters because it offers a mix of downside protection and potential upside, but can change ownership stakes (dilution) and cash obligations depending on whether it’s converted or redeemed.
reverse stock split financial
"on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
initial public offering financial
"upon the completion of the Issuer's initial public offering (the "IPO")"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
Section 16(b) regulatory
"amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Goldman Sachs report in this Form 4 for Attovia Therapeutics (ATTO)?
Goldman Sachs–affiliated entities reported conversions of preferred stock into Attovia common stock tied to the IPO and a series of market-making trades and IPO purchases in common shares, all held indirectly through various managed investment vehicles.
How will potential Section 16(b) profit from ATTO trades be handled by GS&Co?
GS&Co states that any profit potentially recoverable by Attovia under Section 16(b) from the reported market-making trades will be remitted to the issuer, while not conceding that ordinary-course market-making trades create such liability.
AI-generated analysis. How Rhea-AI works. Not financial advice.
